News & Updates

In the treatment of patients with relapsed or refractory follicular lymphoma, adding tafasitamab to lenalidomide and rituximab appears to improve progression-free survival (PFS) while having an acceptable safety profile, according to the phase III inMIND study.

Combining S-1 and oxaliplatin (SOX) as an adjuvant chemotherapy significantly improves overall survival (OS) and disease-free survival (DFS) compared with S-1 alone in patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, according to the final results of the CAPITAL trial presented at ASCO GI 2026.

Dual anti-HER2 blockade with a chemotherapy-free backbone of palbociclib plus letrozole may serve as an alternative treatment to patients with HR-positive/HER2-positive early breast cancer, suggests the phase II TOUCH study, noting similar rates of pathological complete response (pCR) to that of paclitaxel.

Treating gout patients with urate-lowering therapy (ULT) to meet a serum urate level below 6 mg/dL within 12 months results in a reduced risk of major adverse cardiovascular events, as shown in a new user cohort study.

In patients with postendoscopic sphincterotomy (post-EST) bleeding, polysaccharide hemostatic powder (PHP) demonstrates noninferiority to endoscopic clip in the management of post-EST bleeding and is easier to use, reports a study.

Among patients with endometrial cancer receiving treatment with pembrolizumab, those with obesity appear to have worse progression-free survival (PFS), according to a retrospective study.